Search

Displaying results 2561 - 2570 of 5895 in total
  1. Drug

    Nadroparin

    go.drugbank.com/drugs/DB08813
    ApprovedInvestigationalWithdrawn

    Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa.

  2. Drug

    Interferon alfa-n3

    go.drugbank.com/drugs/DB00018
    Approved

    Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).

  3. Drug

    Capromab pendetide

    go.drugbank.com/drugs/DB00089
    ApprovedWithdrawn

    When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer.

  4. Drug

    Erythrityl tetranitrate

    go.drugbank.com/drugs/DB01613
    ApprovedWithdrawn

    A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

  5. Drug

    Cycrimine

    go.drugbank.com/drugs/DB00942
    Approved

    Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.

  6. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical … Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis.

  7. Drug

    Tafenoquine

    go.drugbank.com/drugs/DB06608
    ApprovedInvestigational

    Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine th...

  8. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260651] Therefore, quizartinib is proven to be a beneficial addition to the current AML treatment regimen, although serious side effects such as QT prolongation necessitates further research to optimize … quizartinib's addition to AML standard of care.

  9. Drug

    Exemestane

    go.drugbank.com/drugs/DB00990
    ApprovedInvestigational

    It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

    Products: EXEMESTANE DOC GENERICI, EXEMESTANE MYLAN GENERICS
  10. Drug

    Tildrakizumab

    go.drugbank.com/drugs/DB14004
    ApprovedInvestigational

    The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy